Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Rurioctocog alfa pegol prophylaxis targeting factor VIII (FVIII) troughs ≥1% has shown to be efficacious with an acceptable safety profile in people with hemophilia A (PwHA). The PROPEL trial compared safety and efficacy of 2 target FVIII troughs in PwHA aged 12 to 65 years, with severe disease, ann...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Klamroth, Robert, Windyga, Jerzy, Radulescu, Vlad, Collins, Peter W., Stasyshyn, Oleksandra, Ibrahim, Hishamshah Mohd, Engl, Werner, Tangada, Srilatha D., Savage, William, Ewenstein, Bruce
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2021
Teme:
Thrombosis and Hemostasis
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8039905/
https://ncbi.nlm.nih.gov/pubmed/33150384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005673
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki